Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxo Group Limited

Ryan Michael Fox

Hilary Schenck Eidam

Pui Yee Ng

William Henry Miller

Robert B Perni

Charles A Blum

Richard Dana Caldwell

Jeremy S Disch

Bruce G Szczepankiewicz

Brian H White

Christopher Oalmann

Karsten Koppetsch

Rebecca L Casaubon

Mui Cheung

Krista B Goodman

Guosen Ye

Mark A Hilfiker

Eric Steven Manas

Mark Andrew Seefeld

Clark A Sehon

Gren Z Wang

Carl A Brooks

Pamela A Haile

Andrew Q Viet

Brian W Budzik

Brian Griffin Lawhorn

Lara Kallander

Marlys Hammond

Ronggang Liu

Tram H Hoang

Karen Anderson Evans

Terry Vincent Hughes

Joanne Philp

David G Washburn

Michael Jonathan Bury

Dimitar B Gotchev

Mark Elban

Nathan A Miller

Tamara Ann Miskowski

Jing Zhang

Sharada Manns

James Lamond Ellis

Sarah E Dowdell

Hilary S Eidam

Eric S Manas

Krista Goodman

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Substituted bridged urea analogs as sirtuin modulators

Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

Hydroxy formamide derivatives and their use

The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

The present invention relates to novel substituted bridged urea compounds of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. 

The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

TRPV4 antagonists

The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

The present invention relates to a compound of the following formula: where R-R, R, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.

Spiroindolines as modulators of chemokine receptors

Growing community of inventors

Collegeville, PA, United States of America

Ryan Michael Fox